Role of vasodilators in the treatment of congestive heart failure.
Appreciation of the important role played by peripheral vasoconstriction in the pathophysiology of congestive heart failure (CHF) has led to the widespread use of vasodilators as treatment. Short-term studies show that, regardless of the vasodilator used, the arterial and venous dilatation produced invariably results in improvement in the hemodynamic status of patients. This short-term response, however, does not automatically translate to long-term clinical improvement. The reasons for this are not well understood but such factors as differing mechanisms of action, development of tolerance and unique patterns of regional redistribution of blood flow may all play a modifying role in differentiating one vasodilator from another. Nevertheless, a number of controlled trials have demonstrated sustained symptomatic and functional improvement when vasodilators such as the converting enzyme inhibitors or nitrates are given to patients with CHF.
Levine
T B
TB
D002216:Captopril / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004151:Dipeptides / Q000627:therapeutic use; D004311:Double-Blind Method; D004656:Enalapril; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D011897:Random Allocation; D012039:Regional Blood Flow; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D004151:Dipeptides; D014665:Vasodilator Agents; D006830:Hydralazine; D004656:Enalapril; D002216:Captopril; D007548:Isosorbide Dinitrate; D011224:Prazosin